首页 > 

777 super ace jili

2025-01-24
Intech Investment Management LLC grew its stake in Owens & Minor, Inc. ( NYSE:OMI – Free Report ) by 102.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 45,655 shares of the company’s stock after purchasing an additional 23,055 shares during the period. Intech Investment Management LLC’s holdings in Owens & Minor were worth $716,000 at the end of the most recent quarter. Several other hedge funds have also bought and sold shares of OMI. Deerfield Management Company L.P. Series C boosted its position in Owens & Minor by 30.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 6,371,440 shares of the company’s stock worth $86,014,000 after purchasing an additional 1,493,852 shares in the last quarter. Renaissance Technologies LLC boosted its position in Owens & Minor by 16.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,246,600 shares of the company’s stock worth $16,829,000 after purchasing an additional 176,250 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. boosted its position in Owens & Minor by 374.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 223,074 shares of the company’s stock worth $3,500,000 after purchasing an additional 176,029 shares in the last quarter. Dana Investment Advisors Inc. boosted its position in Owens & Minor by 35.8% in the 2nd quarter. Dana Investment Advisors Inc. now owns 609,040 shares of the company’s stock worth $8,222,000 after purchasing an additional 160,682 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Owens & Minor by 1.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 4,534,204 shares of the company’s stock worth $61,213,000 after purchasing an additional 76,599 shares in the last quarter. Hedge funds and other institutional investors own 98.04% of the company’s stock. Insider Activity In other news, CFO Jonathan A. Leon sold 5,282 shares of the stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $11.82, for a total value of $62,433.24. Following the completion of the sale, the chief financial officer now owns 130,822 shares in the company, valued at approximately $1,546,316.04. This trade represents a 3.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Company insiders own 3.59% of the company’s stock. Wall Street Analysts Forecast Growth Get Our Latest Stock Report on OMI Owens & Minor Trading Up 1.7 % NYSE:OMI opened at $13.54 on Friday. The firm has a market cap of $1.04 billion, a P/E ratio of -20.83, a PEG ratio of 0.46 and a beta of 0.41. The company has a current ratio of 1.09, a quick ratio of 0.45 and a debt-to-equity ratio of 2.11. The stock’s 50 day simple moving average is $13.55 and its 200-day simple moving average is $15.07. Owens & Minor, Inc. has a 12-month low of $11.42 and a 12-month high of $28.35. Owens & Minor ( NYSE:OMI – Get Free Report ) last posted its earnings results on Monday, November 4th. The company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.01. The company had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.68 billion. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. Owens & Minor’s quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.44 earnings per share. Equities analysts anticipate that Owens & Minor, Inc. will post 1.49 EPS for the current year. Owens & Minor Company Profile ( Free Report ) Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers. Featured Stories Want to see what other hedge funds are holding OMI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Owens & Minor, Inc. ( NYSE:OMI – Free Report ). Receive News & Ratings for Owens & Minor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Owens & Minor and related companies with MarketBeat.com's FREE daily email newsletter .777 super ace jili



‘Signed With MAGA’: Hakeem Jeffries Says Bomb Threats Targeted Dems Days After Trump Team Announced Similar Incidents

Biohong Group Initiates the "Microspherization Technology Era" in Skincare 12-05-2024 09:08 PM CET | Fashion, Lifestyle, Trends Press release from: Getnews / PR Agency: Global Social As a global leader in artificial skin manufacturing and a pioneer in the application of regenerative medicine and synthetic biology in China, the core founding team of Biohong Group has discovered through in-depth research on cell development, regeneration, and repair that the root cause of skin aging, dullness, redness, and swelling is cellular issues. Based on a profound understanding and specialized research of skin and cells, the group has successfully developed the groundbreaking "Dermal Targeting Specific Supramolecule Technology." Image: https://www.getnews.info/uploads/84e90ed1ac5e7671d45769e8781ab0bf.jpg This series of technologies upgrades peptides, collagen, and nucleic acid ingredients, which are widely recognized as difficult to penetrate the skin, target, and deliver precisely. By employing interdisciplinary technical methods, these ingredients have been iterated into Peptide Microspheres, Collagen Microspheres and PDRN Microspheres, breaking through their application limitations and directly reaching target cells. This has achieved targeted enhancement of Peptide Microspheres, strong penetration of Collagen Microspheres, and precise anti-aging of PDRN Microspheres, allowing actives to penetrate to the cellular and organelle level, achieving true precision skincare, and bringing new ideas to the revolutionary upgrade of efficacy materials and precise skincare product solutions. Image: https://www.getnews.info/uploads/9cb614189a3800163e0db0cc7ea81333.jpg Peptides, collagen, and PDRN have been highly regarded for their outstanding efficacy, but their application in cosmetics is limited by issues such as stability, permeability, and targeting. Biohong Group has simulated long-chain botulinum-like peptides using computer modeling, modified with myristoyl group to self-assemble into a stable spherical structure, giving it better permeability, stronger stability, and more significant anti-wrinkle and firming effects. This allows the peptides to increase dermal penetration by 393.14% at the 2-hour time point, significantly increasing collagen fiber content by 460%, and Type IV collagen content by 168%. Additionally, these Peptide Microspheres can carry other active ingredients, achieving intelligent assembly and intelligent dissociation for "multi-effect." For example, Peptide Microspheres combined with melittin form Melittin Microspheres, which can not only achieve precise anti-aging but also actively repair damaged and missing collagen in the body, as well as provide anti-inflammatory, soothing, and whitening effects. Image: https://www.getnews.info/uploads/ab12fb3008e452ede69d3789ac398b7e.jpg Biohong Group, based on its self-developed recombinant human type III collagen, uses microspherization technology to compress extremely it into spherical collagen layer by layer with a particle size of less than 120 nanometers. This disruptive innovation not only greatly enhances the permeability and targeting of collagen but also more accurately replenishes the collagen needed by the skin, promoting cell repair and regeneration. It allows for rapid penetration into the skin, reaching the dermis in 0.5 hours, with an increased permeability rate of 255.14%. Image: https://www.getnews.info/uploads/258d1968c012a858d4b0a26f60fad0d4.jpg PDRN, short for PolyDeoxyRiboNucleotide, has been widely used in skin regeneration and wound healing. Due to its poor stability and weak transdermal ability, it is often delivered to the dermis via microneedles or injections. Biohong Group employs its self-developed spherical PDRN technology to compress PDRN into nanoscale, overcoming the challenges of PDRN's difficulty in penetrating the skin and susceptibility to degradation. This allows it to rapidly penetrate the epidermis in 0.5 hours, with a 427.34% increase in dermal permeability after 1 hour, a 68% increase in DNA repair effects, and a 121% increase in collagen fiber content, enabling PDRN to rapidly penetrate cellular layers and precisely target damaged cells, repairing them and promoting collagen production. Image: https://www.getnews.info/uploads/0f43078db7e02eff185d3240a012720b.jpg The Biohong Group is launching precise cellular regulation skincare technology based on regenerative medicine to the world. From regenerative medicine to precision skincare, Biohong Group, based on regenerative medicine, integrates the interdisciplinary advantages of cell biology, dermatology, synthetic biology, and materials science, continuously innovating in the field of precision skincare from cells to organelles. By regulating at the cellular level and reconstructing new efficacy material solutions, it opens a new chapter in precision skincare. On December 5, 2024, Biohong Group held the "Global Launch Conference of Dermal Targeting Specific Supramolecules (DTSS)" in Xi'an, China, where it launched its precision cell regulation achievement - the "Supramolecular Microsphere Technology," marking a revolutionary breakthrough in precision skincare and ushering in the era of precision cell regulation. Media Contact Company Name: Biohong Group Contact Person: Wang Yidan Email: Send Email [ http://www.universalpressrelease.com/?pr=biohong-group-initiates-the-microspherization-technology-era-in-skincare ] Country: China Website: http://www.biohong.com/ This release was published on openPR.

NMMC orders mandatory audit for Navi Mumbai buildings older than 30 yearsAquarius Daily Horoscope Today, Nov 26, 2024 predicts a happy love lifeNEW YORK (AP) — Stocks closed higher on Wall Street, sending the Dow Jones Industrial Average to another all-time high. The Dow added 1% Monday to the record it set on Friday. The S&P 500 rose 0.3%, while the Nasdaq composite rose 0.3%. Treasury yields eased in the bond market after President-elect Donald Trump said he wants Scott Bessent, a hedge fund manager, to be his Treasury Secretary. Smaller companies can feel a big boost from easier borrowing costs, and the Russell 2000 index of small stocks jumped 1.5%, closing just shy of the record high it set three years ago. THIS IS A BREAKING NEWS UPDATE. AP’s earlier story follows below. NEW YORK (AP) — Wall Street is set to break more records Monday as U.S. stocks rise to add to last week’s gains. The S&P 500 was 0.2% higher, as of 3 p.m. Eastern time, and sitting just below its all-time high set two weeks ago. The Dow Jones Industrial Average added 397 points, or 0.9%, to its own record set on Friday, while the Nasdaq composite was 0.1% higher. Treasury yields also eased in the bond market amid what some analysts called a “Bessent bounce” after President-elect Donald Trump said he wants Scott Bessent , a hedge fund manager, to be his Treasury Secretary. Bessent has argued for reducing the U.S. government’s deficit, which is how much more it spends than it takes in through tax and other revenue. Such an approach could soothe worries on Wall Street that Trump’s policies may lead to a much bigger deficit, which in turn would put upward pressure on Treasury yields. After climbing above 4.44% immediately after Trump’s election, the yield on the 10-year Treasury fell back to 4.26% Monday and down from 4.41% late Friday. That’s a notable move, and lower yields help make it cheaper for all kinds of companies and households to borrow money. They also give a boost to prices for stocks and other investments. That helped stocks of smaller companies lead the way, and the Russell 2000 index of smaller stocks jumped 2%. It’s set to top its all-time high, which was set three years ago. Smaller companies can feel bigger boosts from lower borrowing costs because of the need of many to borrow to grow. The two-year Treasury yield, which more closely tracks the market’s expectations for what the Federal Reserve will do with overnight interest rates, also eased sharply. The Fed began cutting its main interest rate just a couple months ago from a two-decade high, hoping to keep the job market humming after bringing high inflation nearly all the way down to its 2% target. But immediately after Trump’s victory, traders had reduced bets for how many cuts the Fed may deliver next year. They were worried Trump's preference for lower tax rates and higher spending on the border would balloon the national debt. . A report coming on Wednesday could influence how much the Fed may cut rates. Economists expect it to show that an underlying inflation trend the Fed prefers to use accelerated to 2.8% last month from 2.7% in September. Higher inflation would make the Fed more reluctant to cut rates as deeply or as quickly as it would otherwise. Goldman Sachs economist David Mericle expects that to slow by the end of next year to 2.4%, but he said inflation would be even lower if not for expected tariff increases on imports from China and autos favored by Trump. In the stock market, Bath & Body Works jumped 19.1% after delivering stronger profit for the latest quarter than analysts expected. The seller of personal care products and home fragrances also raised its financial forecasts for the full year, even though it still sees a “volatile retail environment” and a shorter holiday shopping season this year. Much focus has been on how resilient U.S. shoppers can remain, given high prices across the economy and still-high interest rates. Last week, two major retailers sent mixed messages. Target tumbled after giving a dour forecast for the holiday shopping season. It followed Walmart , which gave a much more encouraging outlook. Another big retailer, Macy’s, said Monday its sales for the latest quarter were in line with its expectations, but it will delay the release of its full financial results. It found a single employee had intentionally hid up to $154 million in delivery expenses, and it needs more time to complete its investigation. Macy’s stock fell 2.9%. Among the market's leaders were several companies related to the housing industry. Monday's drop in Treasury yields could translate into easier mortgage rates, which could spur activity for housing. Builders FirstSource, a supplier or building materials, rose 6.2%. Homebuilders, D.R. Horton, PulteGroup and Lennar all rose at least 5.8%. In stock markets abroad, indexes moved modestly across much of Europe after finishing mixed in Asia. In the crypto market, bitcoin was trading around $96,800 after threatening to hit $100,000 late last week for the first time. ___ AP Business Writer Elaine Kurtenbach contributed. Stan Choe, The Associated Press

The new, 12-team brings with it a promise to be bigger, more exciting, more lucrative. Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably in favor of that finished with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” Alabama athletic director Greg Byrne was gracious, up to a point. “Disappointed with the outcome and felt we were one of the 12 best teams in the country,” he said on social media. He acknowledged — despite all of Alabama’s losses coming against conference opponents this season — that the Tide’s push to schedule more games against teams from other major conferences in order to improve its strength of schedule did not pay off this time. “That is not good for college football," Byrne said. Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. Dec. 21. Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? Dec. 21. The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. Dec. 20. Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner faces ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? , Dec. 21. The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up . AP college football: andSt James's Place scraps glitzy staff gatherings in bid to repair its image By CITY & FINANCE REPORTER Updated: 21:50, 8 December 2024 e-mail View comments St James's Place has scrapped glitzy staff gatherings in a bid to repair its image following criticism over fees and a cost-saving drive that may lead to 500 redundancies. The UK's largest wealth manager has abandoned its annual company meetings in London, which have included lavish dinners and guest speakers such as Bill Clinton and David Beckham, with the coming gathering in January to be held virtually. The FT said a spring sports break at Gleneagles hotel may also be axed. Cost-saving drive: St James's Place has abandoned its annual company meetings in London RELATED ARTICLES Previous 1 Next Wealth manager St James's Place to cut 500 jobs as part of a... Top City boss warns against pensions raid: St James's Place... Share this article Share HOW THIS IS MONEY CAN HELP How to choose the best (and cheapest) stocks and shares Isa and the right DIY investing account DIY INVESTING PLATFORMS AJ Bell AJ Bell Easy investing and ready-made portfolios Learn More Learn More Hargreaves Lansdown Hargreaves Lansdown Free fund dealing and investment ideas Learn More Learn More interactive investor interactive investor Flat-fee investing from £4.99 per month Learn More Learn More Saxo Saxo Get £200 back in trading fees Learn More Learn More Trading 212 Trading 212 Free dealing and no account fee Learn More Learn More Affiliate links: If you take out a product This is Money may earn a commission. These deals are chosen by our editorial team, as we think they are worth highlighting. This does not affect our editorial independence. Compare the best investing account for you Share or comment on this article: St James's Place scraps glitzy staff gatherings in bid to repair its image e-mail Add comment Some links in this article may be affiliate links. If you click on them we may earn a small commission. That helps us fund This Is Money, and keep it free to use. We do not write articles to promote products. We do not allow any commercial relationship to affect our editorial independence.

Intech Investment Management LLC reduced its stake in Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ) by 47.0% during the 3rd quarter, Holdings Channel reports. The fund owned 6,639 shares of the specialty pharmaceutical company’s stock after selling 5,880 shares during the quarter. Intech Investment Management LLC’s holdings in Jazz Pharmaceuticals were worth $740,000 as of its most recent SEC filing. A number of other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Swedbank AB purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $106,936,000. Rubric Capital Management LP purchased a new stake in shares of Jazz Pharmaceuticals during the second quarter worth approximately $65,812,000. Pacer Advisors Inc. increased its stake in shares of Jazz Pharmaceuticals by 40.7% during the second quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares during the period. Baupost Group LLC MA raised its holdings in Jazz Pharmaceuticals by 52.8% in the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after acquiring an additional 440,552 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in Jazz Pharmaceuticals by 1,808.4% during the 2nd quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company’s stock worth $48,122,000 after acquiring an additional 427,246 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors. Insider Activity at Jazz Pharmaceuticals In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the transaction, the executive vice president now directly owns 33,048 shares in the company, valued at approximately $4,078,453.68. The trade was a 10.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink . Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the company’s stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. The trade was a 8.85 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold a total of 6,110 shares of company stock worth $720,160 in the last 90 days. 4.20% of the stock is owned by insiders. Analyst Ratings Changes View Our Latest Analysis on JAZZ Jazz Pharmaceuticals Price Performance JAZZ stock opened at $121.59 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company has a market capitalization of $7.35 billion, a P/E ratio of 17.13, a PEG ratio of 1.03 and a beta of 0.57. The business has a 50 day simple moving average of $114.87 and a 200-day simple moving average of $111.12. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $134.17. Jazz Pharmaceuticals Profile ( Free Report ) Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. Recommended Stories Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals plc ( NASDAQ:JAZZ – Free Report ). Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .Apple Cash is more than just a peer-to-peer (P2P) payment service — it can be used to shop online, in stores or to make in-app purchases.Navy Day 2024: Spectators to witness `Operational Demonstration` on Dec 4

Previous: 123 jili super ace
Next: jili super ace app download for android